Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jun;30(6):461-462.
doi: 10.1038/s41422-020-0330-9.

Enabling anti-tumor immunity by unleashing ILC2

Irene Mattiola  1   2   3 , Andreas Diefenbach  4   5   6
Affiliations
Comment

Enabling anti-tumor immunity by unleashing ILC2

Irene Mattiola et al. Cell Res. 2020 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. ILC2-mediated orchestration of anti-tumor immunity against PDAC.
a ILC2 infiltration in PDAC is dependent on (endogenous) IL33. b Tumor immunotherapy with rIL33 induces ILC2 proliferation, activation, and CCL5 production by ILC2. High levels of CCL5 promote the recruitment of CD103+ DCs to the tumor bed, enhancing the priming of CD8+ T cells and thus their anti-tumor functions. c Combination of rIL33 treatment with anti-PD1 checkpoint blockade synergistically enhances anti-tumor immunity most likely by further unleashing ILC2 function. Illustrations were prepared with BioRender (BioRender.com).
See this image and copyright information in PMC

Comment on

  • ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity.
    Moral JA, Leung J, Rojas LA, Ruan J, Zhao J, Sethna Z, Ramnarain A, Gasmi B, Gururajan M, Redmond D, Askan G, Bhanot U, Elyada E, Park Y, Tuveson DA, Gönen M, Leach SD, Wolchok JD, DeMatteo RP, Merghoub T, Balachandran VP. Moral JA, et al. Nature. 2020 Mar;579(7797):130-135. doi: 10.1038/s41586-020-2015-4. Epub 2020 Feb 19. Nature. 2020. PMID: 32076273 Free PMC article.

References

    1. Hanahan D, Weinberg RA. Cell. 2011;144:646–674. doi: 10.1016/j.cell.2011.02.013. - DOI - PubMed
    1. Sonnenberg GF, Hepworth MR. Nat. Rev. Immunol. 2019;19:599–613. doi: 10.1038/s41577-019-0194-8. - DOI - PMC - PubMed
    1. Spits H, et al. Nat. Rev. Immunol. 2013;13:145–149. doi: 10.1038/nri3365. - DOI - PubMed
    1. Gasteiger G, Fan X, Dikiy S, Lee SY, Rudensky AY. Science. 2015;350:981–985. doi: 10.1126/science.aac9593. - DOI - PMC - PubMed
    1. Diefenbach A, Gnafakis S, Shomrat O. Immunity. 2020;52:452–463. doi: 10.1016/j.immuni.2020.02.016. - DOI - PubMed